TICKERNERD
Menu
NRSNNRSNHealthcare · Biotechnology

NRSN Stock Forecast: Neurosense Therapeutics Ltd. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$3.48

The 3 Wall Street analysts covering Neurosense Therapeutics Ltd. hold a median 12-month price target of $116 — +3233.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 12 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.6M
Ticker Nerd rank
4 / 100
Median analyst target
$116
Analysts covering
3
Revenue$0.0
Operating income−$1.8M
Net income−$1.8M
Quarterly, 6 quarters to 31 Dec 2024 · latest quarter's figure shown
Ticker Nerd rank

NRSN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neurosense Therapeutics Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Volatility
46
Revisions
39
Accruals
8
Growth
8
Value
6
Momentum
5
Quality
5
Issuance
0

Size (94): Smaller than most of the companies we track.

Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NRSN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRSN, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $52Median $116High $180

The green dot is the last close — the median target sits +3233.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Sept 2026HC Wainwright & Co.MaintainsBuy$8.00 → $52
3 Sept 2026HC Wainwright & Co.InitiatesBuy$8.00
3 Sept 2026HC Wainwright & Co.InitiatesBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy$14
8 Apr 2026D. Boral CapitalMaintainsBuy—
25 Mar 2026D. Boral CapitalMaintainsBuy—
17 Mar 2026D. Boral CapitalMaintainsBuy—
10 Mar 2026Roth CapitalInitiatesBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—
22 Dec 2025D. Boral CapitalMaintainsBuy—
24 Nov 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
10 July 2025D. Boral CapitalMaintainsBuy—
12 May 2025D. Boral CapitalInitiatesBuy—
16 Dec 2024Maxim GroupDowngradeHold—
17 July 2023Alliance Global PartnersInitiatesBuy$7.50
7 Jan 2022Maxim GroupInitiatesBuy$7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRSN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NRSN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Neurosense Therapeutics Ltd. (NRSN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.9×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
—
EV / EBITDA
−0.6×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−2175.0%

Higher than 1% of US stocks

Return on assets
−247.3%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neurosense Therapeutics Ltd. (NRSN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neurosense Therapeutics Ltd. has a market value of $6.6M and an enterprise value of $6.2M.

  • Revenue in the twelve months to 31 Dec 2024: $0.0.

  • Net income over the same four quarters: −$10.2M.

  • Shares outstanding: 32.6M.

  • Trailing P/E: −7.9×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Neurosense Therapeutics Ltd. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Dec 2024 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

NRSN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NRSNNeurosense Therapeutics Ltd.$6.6M
4
ENVBEnveric Biosciences, Inc.$6.6M
17
FBLGFibroBiologics, Inc.$6.7M
45
LEXXLexaria Bioscience Corp.$6.9M
26
TRAWTraws Pharma, Inc.$6.3M
51
ALZNAlzamend Neuro, Inc.$6.3M
29
XCURExicure, Inc.$6.9M
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neurosense Therapeutics Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NRSN news & analysis

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

PRNewsWire · 13 Oct 2026neutral

NeuroSense said its shares continue to trade on Nasdaq while it awaits a Panel decision, after regaining compliance with the minimum bid price requirement. The company cited a Health Canada New Drug Submission targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027.

Why it matters — The Nasdaq Panel decision and the stated regulatory and funding milestones are developments NRSN watchers may follow.

NeuroSense Provides Update on Nasdaq Listing Compliance

PRNewsWire · 2 Oct 2026positive

NeuroSense Therapeutics Ltd. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement.

Why it matters — This update indicates progress on one Nasdaq listing requirement while the company continues working to resolve the remaining minimum market value condition, which is relevant to its continued listing status.

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

PRNewsWire · 28 Sept 2026neutral

NeuroSense Therapeutics announced that management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026, and will be available for one-on-one investor meetings during the event. The announcement was made via a press release from Cambridge, Mass.

Why it matters — NRSN watchers may care as the company's participation offers a formal venue for investors to engage directly with management about the business.

NeuroSense Provides Business Update and Progress for the First Half of 2026

PRNewsWire · 25 Sept 2026neutral

NeuroSense Therapeutics Ltd. issued a business update and progress report covering the first half of 2026, announced from its Cambridge, Mass. location on Sept. 25, 2026, per a PRNewswire release.

Why it matters — A periodic business update provides NRSN watchers with an overview of the company's first-half 2026 progress.

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 10 Sept 2026neutral

NeuroSense Therapeutics announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15 at 4:30 p.m. ET. Management will also be available for one-on-one investor meetings during the conference.

Why it matters — The presentation and investor meetings give NRSN watchers an opportunity to hear directly from management and engage with the company at a major industry conference.

FAQ

Frequently asked questions about NRSN stock

What is the NRSN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Neurosense Therapeutics Ltd. have a median 12-month price target of $116, with estimates ranging from $52 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRSN stock a buy right now?

Of the 3 analysts covering Neurosense Therapeutics Ltd., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurosense Therapeutics Ltd. 4 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRSN?

As at 12 Oct 2026, Neurosense Therapeutics Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will NRSN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +3233.3% from the last close, and Ticker Nerd's factor model ranks Neurosense Therapeutics Ltd. 4 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRSN stock forecast for 2030?

No analyst covering Neurosense Therapeutics Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRSN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $52 to $180 over the next 12 months.

What does Neurosense Therapeutics Ltd. do?

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases.

What is the latest news on NRSN?

The most recent item we track (PRNewsWire, 13 Oct 2026): "NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones". NeuroSense said its shares continue to trade on Nasdaq while it awaits a Panel decision, after regaining compliance with the minimum bid price requirement. The company cited a Health Canada New Drug Submission targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027.

Company

About Neurosense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead program, PrimeC, is an oral combination therapy designed for amyotrophic lateral sclerosis (ALS), while its broader pipeline includes research programs for Alzheimer’s disease and Parkinson’s disease. The company develops targeted therapeutic approaches intended to address complex neurological conditions with significant unmet medical need. NeuroSense Therapeutics Ltd. operates in the global biopharmaceutical market, where it contributes to the advancement of novel drug candidates through clinical and preclinical development. Based in Herzliya, Israel, the company is positioned within the specialized field of neuroscience-focused drug discovery and development.

CEO Mr. Alon Ben-Noon · 17 employees · Israel · https://www.neurosense-tx.com